Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Lavallade, H
Right arrow Articles by Blaise, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Lavallade, H
Right arrow Articles by Blaise, D
Haematologica, Vol 91, Issue 10, 1438-1440
Copyright © 2006 by Ferrata Storti Foundation

Comparative Study

Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation

H de Lavallade, M Mohty, C Faucher, S Furst, J El-Cheikh, and D Blaise

This study investigated the use of low dose methotrexate (MTX) (5 mg/m2/infusion) for the treatment of graft-versus-host disease (GVHD), after failure of corticosteroids. Twelve patients had refractory acute GVHD, while eight received MTX for severe chronic GVHD and/or the side effects of corticosteroids. Thirteen patients responded to MTX with six complete remissions and little toxicity, suggesting that low dose MTX is beneficial in refractory GVHD and deserves further investigations.




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.